IL304805A - Viral constructs for use in enhancing t-cell priming during vaccination - Google Patents
Viral constructs for use in enhancing t-cell priming during vaccinationInfo
- Publication number
- IL304805A IL304805A IL304805A IL30480523A IL304805A IL 304805 A IL304805 A IL 304805A IL 304805 A IL304805 A IL 304805A IL 30480523 A IL30480523 A IL 30480523A IL 304805 A IL304805 A IL 304805A
- Authority
- IL
- Israel
- Prior art keywords
- augmenting
- priming
- cells during
- viral constructs
- during vaccination
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 230000003190 augmentative effect Effects 0.000 title 1
- 230000037452 priming Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144834P | 2021-02-02 | 2021-02-02 | |
| PCT/US2022/014970 WO2022169895A1 (en) | 2021-02-02 | 2022-02-02 | Viral constructs for use in enhancing t-cell priming during vaccination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304805A true IL304805A (en) | 2023-09-01 |
Family
ID=82741782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304805A IL304805A (en) | 2021-02-02 | 2023-07-27 | Viral constructs for use in enhancing t-cell priming during vaccination |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240344082A1 (https=) |
| EP (1) | EP4288076A4 (https=) |
| JP (1) | JP2024505274A (https=) |
| KR (1) | KR20240001116A (https=) |
| CN (1) | CN117177763A (https=) |
| AU (1) | AU2022215566A1 (https=) |
| BR (1) | BR112023015467A2 (https=) |
| CA (1) | CA3206004A1 (https=) |
| IL (1) | IL304805A (https=) |
| MX (1) | MX2023009008A (https=) |
| TW (1) | TW202246514A (https=) |
| WO (1) | WO2022169895A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111533785B (zh) * | 2020-02-11 | 2022-03-08 | 北京市肿瘤防治研究所 | 靶向免疫检查点tim3结合肽及其应用 |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| WO2024206243A1 (en) * | 2023-03-24 | 2024-10-03 | Geovax. Inc. | Pan-betacoronavirus vaccines and uses thereof |
| WO2025072383A1 (en) * | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| CN117904069B (zh) * | 2024-01-04 | 2025-07-15 | 华中农业大学 | VirEN蛋白介导的DNA拼接和基因编辑方法 |
| GB202409284D0 (en) * | 2024-06-27 | 2024-08-14 | Univ Oxford Innovation Ltd | Mrna platform |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| ATE315660T1 (de) | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| US20100305002A1 (en) | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CN115300622A (zh) * | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| US10098950B2 (en) | 2016-09-15 | 2018-10-16 | Leidos, Inc. | PD-1 Peptide Inhibitors |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| EP3796891A4 (en) * | 2018-04-11 | 2022-04-20 | Precision Molecular Inc. | THERAPEUTIC CONSTRUCTS FOR TREATMENT OF CANCER |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
-
2022
- 2022-02-02 JP JP2023547031A patent/JP2024505274A/ja active Pending
- 2022-02-02 AU AU2022215566A patent/AU2022215566A1/en active Pending
- 2022-02-02 MX MX2023009008A patent/MX2023009008A/es unknown
- 2022-02-02 KR KR1020237029493A patent/KR20240001116A/ko active Pending
- 2022-02-02 CN CN202280021291.5A patent/CN117177763A/zh active Pending
- 2022-02-02 EP EP22750341.4A patent/EP4288076A4/en active Pending
- 2022-02-02 WO PCT/US2022/014970 patent/WO2022169895A1/en not_active Ceased
- 2022-02-02 CA CA3206004A patent/CA3206004A1/en active Pending
- 2022-02-02 BR BR112023015467A patent/BR112023015467A2/pt unknown
- 2022-02-07 TW TW111104426A patent/TW202246514A/zh unknown
-
2023
- 2023-07-27 IL IL304805A patent/IL304805A/en unknown
- 2023-08-01 US US18/229,070 patent/US20240344082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4288076A4 (en) | 2025-01-22 |
| CA3206004A1 (en) | 2022-08-11 |
| JP2024505274A (ja) | 2024-02-05 |
| TW202246514A (zh) | 2022-12-01 |
| CN117177763A (zh) | 2023-12-05 |
| BR112023015467A2 (pt) | 2023-10-10 |
| AU2022215566A9 (en) | 2025-01-30 |
| MX2023009008A (es) | 2023-10-05 |
| AU2022215566A1 (en) | 2023-08-17 |
| WO2022169895A1 (en) | 2022-08-11 |
| US20240344082A1 (en) | 2024-10-17 |
| KR20240001116A (ko) | 2024-01-03 |
| EP4288076A1 (en) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304805A (en) | Viral constructs for use in enhancing t-cell priming during vaccination | |
| CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
| BR112013020070A8 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
| EA202090759A3 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
| CO2017007105A2 (es) | Nuevos virus de tilapia | |
| CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
| AR110632A1 (es) | Vectores del adenovirus canino | |
| Sawant et al. | Development of a DNA vaccine for chicken infectious anemia and its immunogenicity studies using high mobility group box 1 protein as a novel immunoadjuvant indicated induction of promising protective immune responses | |
| MX2020008394A (es) | Tratamiento que usa arn que codifica citoquinas. | |
| EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| EA202092990A2 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу | |
| CO2022004470A2 (es) | Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| ZA202206750B (en) | Vaccines against african swine fever virus, and methods of using same | |
| EA201690115A1 (ru) | Комбинированные иммуногенные композиции | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
| CL2018002900A1 (es) | Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos. | |
| MX2017008087A (es) | Virus de la viruela porcina recombinante y vacunas. | |
| CO6670515A2 (es) | Vectores de parapoxvirus | |
| BR112021023348A2 (pt) | Vacinação oral à base de levedura | |
| IL308407A (en) | Novel protein and nucleic acid sequences for covid-19 vaccines | |
| MX361804B (es) | Vacunas genéticas contra el virus hendra y el virus nipah. |